Acadia Pharmaceuticals has announced that its Phase III COMPASS PWS trial evaluating intranasal carbetocin (ACP-101) in patients with hyperphagia in Prader-Willi syndrome (PWS) did not meet its primary endpoint. 

The treatment did not demonstrate a statistically significant improvement over placebo on the study’s primary endpoint, change from baseline to week 12 on the Hyperphagia Questionnaire for Clinical Trials (HQ-CT), nor was there separation from placebo on any secondary endpoint.  

However, the safety and tolerability profile of intranasal carbetocin was consistent with previous clinical trials, showing a low rate of adverse events. 

The price of the company’s shares dropped by 11.7% following the announcement. 

“We are disappointed by these findings, especially for Prader-Willi syndrome patients, their families and the entire community,” said Elizabeth Thompson, Acadia’s Head of Research and Development. “I want to thank the many patients, families, study site personnel, and physicians who participated in the COMPASS PWS study as well as the intranasal carbetocin clinical development programme, for their dedication and contributions in this important study.  

“We are committed to sharing a summary of the data in the future to ensure learning for the PWS community; however, given these results, we do not intend to investigate intranasal carbetocin any further.” 

COMPASS PWS evaluated intranasal carbetocin 3.2mg three times daily (TID) in 175 enrolled children and adults aged five to 30 years with PWS. 

“Despite this disappointment, Acadia is well-positioned to deliver long-term, sustainable growth supported by two approved products projected to generate over $1 billion in net sales in 2025, and a robust pipeline that includes eight disclosed and multiple undisclosed programmes,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. 

The company’s clinical-stage development efforts are focused on Alzheimer’s disease psychosis, Lewy Body Demetia psychosis and multiple other programmes targeting neuroscience and neuro-rare diseases.

Diana Turner, Deputy Editor, DDW